HC Wainwright Has Optimistic Outlook of ATNM FY2025 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities research analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Monday, November 17th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($1.09) per share for the year, up from their previous forecast of ($1.26). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.91) EPS.

Actinium Pharmaceuticals Price Performance

Shares of Actinium Pharmaceuticals stock opened at $1.43 on Wednesday. The stock has a market capitalization of $44.61 million, a P/E ratio of -1.03 and a beta of -0.25. The business has a 50 day simple moving average of $1.51 and a two-hundred day simple moving average of $1.58. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.41.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Actinium Pharmaceuticals by 0.9% in the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after buying an additional 12,703 shares during the last quarter. Two Sigma Investments LP raised its holdings in Actinium Pharmaceuticals by 403.4% in the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock valued at $375,000 after acquiring an additional 187,748 shares during the last quarter. Gagnon Securities LLC purchased a new position in Actinium Pharmaceuticals in the 1st quarter worth approximately $365,000. Jane Street Group LLC purchased a new position in Actinium Pharmaceuticals in the 2nd quarter worth approximately $306,000. Finally, Invesco Ltd. increased its holdings in shares of Actinium Pharmaceuticals by 1,135.9% in the first quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock valued at $247,000 after purchasing an additional 141,130 shares during the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).